Neovacs links with Spanish firm on IFNα cytokine production

French biotech firm Neovacs (Alternext Paris: ALNEV) is moving forward its newly-acquired of interferon alpha (IFNα) technology, collaborating with a Spanish company for production.

It has entered into partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs. This new collaboration follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from Argentinean firm Amegabiotech.

This license agreement will allow Neovacs to directly transfer Amegabiotech’s technology to the production site of 3P Biopharmaceuticals, which will ensure the manufacture of the IFNα cytokine. As the only Spanish manufacturer of biological products in the healthcare field, 3P Biopharmaceuticals has a successful track record working with top pharma and biotech companies throughout Europe and the USA, according to Neovacs.